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During canonical G protein signaling, G
protein-coupled receptors (GPCRs)
function as guanine exchange factors
(GEFs) at the plasma membrane. Lo et al.
show that GIV, a non-receptor GEF,
activates Gi proteins at the Golgi and, via
modulation of Arf1 signaling, regulates
vesicle trafficking and Golgi organization.
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A long-held tenet of heterotrimeric G protein signal
transduction is that it is triggered by G protein-
coupled receptors (GPCRs) at the PM. Here, we
demonstrate that Gi is activated in the Golgi by
GIV/Girdin, a non-receptor guanine-nucleotide ex-
change factor (GEF). GIV-dependent activation of
Gi at the Golgi maintains the finiteness of the cyclical
activation of ADP-ribosylation factor 1 (Arf1), a
fundamental step in vesicle traffic in all eukaryotes.
Several interactions with other major components
of Golgi trafficking—e.g., active Arf1, its regulator,
ArfGAP2/3, and the adaptor protein b-COP—enable
GIV to coordinately regulate Arf1 signaling. When
the GIV-Gai pathway is selectively inhibited, levels
of GTP-bound Arf1 are elevated and protein trans-
port along the secretory pathway is delayed. These
findings define a paradigm in non-canonical G pro-
tein signaling at the Golgi, which places GIV-GEF at
the crossroads between signals gated by the trimeric
G proteins and the Arf family of monomeric GTPases.
INTRODUCTION
Canonical G protein signaling is believed to emanate exclusively
from the plasma membrane (PM) (Gilman, 1987), triggered by
ligand-bound G protein coupled receptors (GPCRs) that serve
as guanine nucleotide exchange factors (GEFs). However, gath-
ering evidence indicates that trimeric G proteins are also acti-
vated independent of GPCRs at different intracellular organelles
and that such activation plays crucial roles in cells (Hewavithar-
ana and Wedegaertner, 2012). The Golgi complex has emerged
as amajor hub for such intracellular signaling because it contains
G proteins and a plethora of modulators of G protein signaling;
e.g., kinases, phosphatases, and phospholipases (Cancino
and Luini, 2013).
Heterotrimeric G proteins were detected in the Golgi over two
decades ago (Barr et al., 1992; Stow et al., 1991), and numerous
studies have provided clues that they may regulate membrane
traffic and maintain the structural integrity of the Golgi (Cancino
and Luini, 2013). However, the concept of G protein activation atDevethe Golgi and the potential impact of such activation aremet with
skepticism, primarily due to the lack of direct proof of G protein
activation. We recently discovered a non-receptor guanidine ex-
change factor (GEF) for Gai, GIV (Garcia-Marcos et al., 2009)
(also known as Girdin), a multi-modular signal transducer that
binds phosphatidylinositol 4-phosphate (PI(4)P; see Enomoto
et al., 2005) and primarily localizes to the Golgi on COPI vesicles
(Le-Niculescu et al., 2005). Activation of Gai via GIV’s GEF motif
has been implicated in the regulation of diverse cellular pro-
cesses including cell migration, endosomal trafficking, and auto-
phagosome maturation (Garcia-Marcos et al., 2015). Because
GIV and trimeric G proteins localize on Golgi membranes and
because GIV is a bona fide GEF for Gai (Garcia-Marcos et al.,
2009), we investigated whether GIV-GEF activates Gai in the
Golgi. We provide direct evidence that activation of Gai by GIV
in the Golgi affects two fundamental functions of the Golgi;
i.e., vesicle trafficking and the structural organization of the Golgi
stacks, both via modulation of Arf1 signaling. These findings
break the impasse on whether Gai is functionally active in
the Golgi.RESULTS AND DISCUSSION
GIV Binds and Activates Gai in the Golgi Complex
We previously showed that Gai3 is found in both the Golgi region
and at the PM (Weiss et al., 2001), and that GIV colocalizes with
Gai3 at both sites (Le-Niculescu et al., 2005). By double immuno-
staining, GIV and Gai3 show a perinuclear, Golgi-like distribu-
tion, and colocalize with b-COP, one of the COPI coatomer
subunits (Figure S1A). To determine if GIV and Gai3 interact in
the Golgi, we performed proximity ligation assays (PLA) (So¨der-
berg et al., 2006) to detect in situ GIV-Gai3 complexes in COS7
cells transfected with Gai3 internally tagged with yellow fluores-
cent protein (YFP) (Gai3-YFP). PLA signals were detected
between endogenous GIV and Gai3-YFP in the Golgi region (Fig-
ure 1A), indicating that they interact (i.e., the maximum distance
between the two is %30–40 nanometers; see So¨derberg et al.,
2006). However, GIV did not interact with the Gai3-YFP W258F
mutant (Figure 1A), henceforth referred to as Gai3-WF, which
cannot bind or be activated by GIV, but interacts with Gbg,
GPCRs, and Gai regulators (Garcia-Marcos et al., 2010) and
localizes to the Golgi similar to Gai3-wild-type (WT) (Figure S1B).
Next, we asked if the Gai that resides at the Golgi is active and if
such activation requires GIV. To this end, we used a previouslylopmental Cell 33, 189–203, April 20, 2015 ª2015 Elsevier Inc. 189
Figure 1. GIV Activates Gai at the Golgi via Its GEF Motif
(A) COS7 cells transfectedwith YFP-taggedGai3-WT or theGai3-WFmutant were analyzed for interaction between endogenousGIV andGai3-YFP by in situ PLA
using mouse anti-GFP and rabbit anti-GIV antibodies. Red spots indicate the presence of interaction. Insets show the Golgi region at higher magnification (white
dashed box). The scale bar represents 10 mm.
(B) Schematic for the Gai1-YFP and Gb1-CFP constructs used as paired FRET probes in (D and E). FRET indicates the presence of inactive trimer, whereas
activation of Gi is associated with loss of FRET.
(C) COS7 cells expressing Gai1-YFP (pseudo-colored green) and Man II-CFP (pseudo-colored red) were fixed and analyzed by confocal microscopy. A high
degree of colocalization (yellow pixels) indicates that the Gai1-YFP predominantly localizes on the Golgi.
(D and E) Control (Scr shRNA) andGIV-depleted (GIV shRNA) COS7 cells (see also Figure S1C) were cotransfected with Gai1-YFP, Gb1-CFP, andGg2 (untagged)
and live cells were analyzed by FRET imaging at steady-state, in the presence of 10% serum. Representative freeze-frame YFP, CFP, and FRET images are
shown. FRET image panels display intensities of acceptor emission due to efficient energy transfer in each pixel.
(F) Bar graph displays FRET efficiency (y axis). FRET at the Golgi is strong in GIV-depleted cells (E); FRET efficiency = 0.37 ± 0.06), but minimal in controls (D);
FRET efficiency = 0.061 ± 0.01). Results are expressed as mean ± SD. Data represent five ROIs analyzed over the pixels corresponding to the Golgi of 3–5 cells
from five independent experiments.
(G) Control (Ctrl siRNA) and GIV-depleted (GIV siRNA) COS7 cells (see also Figure S1D) maintained in 10% serum were fixed and stained for active Gai (green;
anti-Gai:GTP mAb) and Man II (red) and analyzed by confocal microscopy. Activation of Gai was detected frequently in control, but not in GIV-depleted cells.
When detected, active Gai colocalizes with Man II (yellow pixels in upper panel).
(H) Bar graph displays % cells that stain positive for active Gai (y axis) in control and GIV-depleted cells analyzed in (G).
(I) Active Gai is detected frequently in cells expressing GIV-WT (upper), but not in those expressing GIV-FA (lower). When detected, active Gai colocalizes with
GIV-HA (yellow pixels in merged panel). COS7 cells expressing HA-tagged GIV-WT or GIV-FA were fixed and stained for GIV (red; anti-HA mAb) and active Gai
(green; anti-Gai:GTP mAb) and analyzed by confocal microscopy.
(J) Bar graph displays % cells expressing GIV-HA (WT or FA) that stain positive for active Gai (y axis) in (I).
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well-established Fo¨rster resonance energy transfer (FRET)-
based assay in living cells (Gibson and Gilman, 2006) in which
dissociation of Gai1-YFP and CFP-Gb1g2 (low FRET) is used as
a surrogate marker for ‘‘activation’’ of Gi (Figure 1B). We found
that Gai1-YFP localized to the Golgi (Figure 1C), but showed
minimal FRET with CFP-Gb1g2 heterodimers in that region
(0.061 ± 0.01; Figure 1D) in control COS7 cells, indicative of
the presence of active G proteins at the Golgi. By contrast, in
GIV-depleted COS7 cells (Figure S1C) FRET efficiency was
significantly higher at the Golgi region (6-fold) (0.37 ± 0.06; Fig-
ures 1E and 1F), indicating that in the absence of GIV, Gai stays
complexedwith Gbg as inactive heterotrimers at theGolgi. Using
anti-Gai:guanosine-50-triphosphate (GTP) mAb, which specif-
ically recognizes the GTP-bound active conformation of the
Gai (1/2/3) proteins (Lane et al., 2008), we further confirmed
that active Gai was frequently detected at the Golgi in control
cells, where it colocalized with Man II, but not detected in GIV-
depleted cells (Figures 1G, 1H, and S1D). As anticipated, we
found that the GEF motif of GIV is essential for activation of
Gai at the Golgi because active Gai was frequently detected at
the perinuclear Golgi region in COS7 cells expressing WT GIV
(GIV-WT), but not in cells expressing a GEF-deficient GIV
mutant, GIV-FA that cannot bind or activate Gai (Garcia-Marcos
et al., 2009) (Figures 1I and 1J). These results demonstrate that
Gai is active in the Golgi and that such activation requires GIV.
GIV Interacts with b-COP on COPI Vesicles
Next, we asked with which population of Golgi-derived vesicles
GIV and Gai3 are associated. Previously, we showed that GIV
colocalizes with COPI vesicles and Golgi membranes by immu-
nofluorescence and immunogold electron microscopy labeling
(Le-Niculescu et al., 2005). First, we prepared a crude mem-
brane fraction (100,0003 g pellet) from COS7 cells (Figure S2A)
and immunoisolated COPI membranes from this fraction using
CM1A10, an antibody that recognizes the assembled COPI
coat (coatomer) (Palmer et al., 1993), and verified that both
GIV and Gai3 were enriched on COPI-coated membranes (Fig-
ure 2A). Next, we asked if GIV interacts with COPI coat proteins
in cells. We detected PLA signals between endogenous GIV
and COPI-coated membranes in the Golgi as marked by ex-
pressing YFP-tagged b-Galactosyl transferase (GalT), as well
as scattered throughout the cytoplasm (Figures 2B, S2B, and
S2C left). This distribution of PLA signal indicates that GIV asso-
ciates with COPI at the Golgi and the peripheral ERGIC, one of
the major organelles where COPI-coated vesicles are found be-
sides the Golgi (Oprins et al., 1993). Pull-down assays from
HeLa cells expressing glutathione S-transferases (GST)-tagged
full-length GIV showed that b-COP, a component of the hepta-
meric COPI coat complex, as well as Gai3, used as a positive
control, bound to GIV (Figure S2D). Finally, we found that GIV
coimmunoprecipitates with b-COP, but such interaction is lost
when cells are incubated with 5 mg/ml brefeldin (BFA), a fungal
metabolite that prevents the binding of COPI coats to mem-
branes and releases b-COP into the cytosol (Figure 2C). BFA
treatment also significantly reduced (by 62%) the signals de-
tected by in situ PLA between GIV and COPI vesicles (Fig-
ure S2C, right), indicating that GIV and b-COP interact only
when the latter can be recruited to membranes. No such inter-
action was seen between GIV and SEC13, a component ofDeveCOPII vesicle coats (Figure S2E). Together these data reveal
that GIV forms a complex specifically with COPI coatomer on
membranes.
GIV and Its GEF Function Are Required for Uncoating of
COPI Vesicles
Next, we asked if depletion of GIV alters the association of
COPI with membranes. Membrane-cytosol fractionation studies
showed that compared to controls, membrane-associated
b-COP was increased by 42% in GIV-depleted cells (Figures
2D and 2E). When we carried out similar assays in GIV-depleted
cells that were infected with adenovirus containing short inter-
fering (si)RNA-resistant GIV-WT or the GIV-FA mutant that
does not bind or activate Gai3 (Garcia-Marcos et al., 2009), we
found that membrane-associated b-COP was increased by
37% in cells expressing inactive GIV-FA compared to active
GIV-WT (Figures 2F and 2G). These findings indicate that the
GEF motif, via which GIV activates Gai3, is essential to reduce
membrane-association of b-COP.
Next, we explored the effect of GIV depletion on the distribu-
tion of COPI vesicles by immunofluorescence. In cells treated
with control siRNA, b-COP was mostly associated with Golgi
membranes and a few COPI vesicles concentrated in and
around the Golgi region, whereas in GIV-depleted cells, abun-
dant COPI vesicles were seen dispersed peripherally throughout
the cytoplasm (Figure 2H). Quantification revealed that the pe-
ripheral pool of vesicles was increased 2.6-fold after GIV
depletion (Figure 2I). A similar 2-fold increase in the peripheral
pool of COPI vesicles was also seen in cells expressing the GEF-
deficient GIV-FA mutant when compared to those expressing
GIV-WT (Figures 2J and S2F), indicating that GIV and its GEF
motif are essential for normal distribution of COPI vesicles. To
corroborate accumulation of COPI vesicles after GIV depletion,
we prepared enriched vesicle fractions by differential centrifuga-
tion and found that b-COP was increased 2-fold in vesicle
fractions (100,000 3 g pellet fraction, [P3]) obtained from GIV-
depleted cells (Figures 2K and 2L), which is consistent with the
immunofluorescence findings (Figures 2H and 2I), indicating
that COPI-coated vesicles accumulate after GIV depletion.
GM130, used as a Golgi marker, was concentrated in the Golgi
enriched fraction (15,000 3 g pellet, P2) and was not detected
in the enriched vesicle fraction (Figure 2K), indicating that Golgi
membranes were not present in this fraction and thus not vesic-
ulated during homogenization. Furthermore, we confirmed by
immunoblotting that the observed changes in distribution of
b-COP were not due to changes in the total levels of the protein
(Figures S2G and S2H). The accumulation of budded vesicles
with b-COP coats in the cell periphery (Figures 2H and 2I),
together with the shift in b-COP from the cytosol to membrane
fractions (Figures 2D and 2E), point to a defect in uncoating of
COPI vesicles in the absence of GIV, and suggest a role for
GIV in facilitating the uncoating of COPI vesicles. The results
with the GEF deficient GIV-FA mutant imply that activation of
Gai3 by GIV is required for uncoating.
Next, we analyzed the nature of the compartments where the
COPI coat accumulated. Immunofluorescence labeling showed
that in control cells, there were very few b-COP-stained puncta
(COPI vesicles) in the cell periphery (away from the Golgi; Fig-
ure S3A), showing limited colocalization with or proximity tolopmental Cell 33, 189–203, April 20, 2015 ª2015 Elsevier Inc. 191
Figure 2. GIV Associates with COPI Vesicles
and Is Required for Uncoating of COPI
Vesicles
(A) COPI membranes were immunoisolated from a
crude membrane (100,000 3 g pellet; see Fig-
ure S2A) fraction prepared from COS7 cells using
mAb CM1A10 (which recognizes coatomer), and
bound immune complexes were analyzed for GIV,
b-COP, Gai3, and transferrin receptor (TfR, a
negative control) by immunoblotting (IB).
(B) HeLa cells expressing GalT-YFP (Golgi marker,
pseudocolored green) were fixed and analyzed
for interactions between GIV and b-COP by in situ
PLA (red). Nuclei = DAPI (blue). The scale bar rep-
resents 10 mm. Negative control (S2B) showed no
signal.
(C) HeLa cells expressing GIV-FLAG were treated
or not with 5 mg/ml BFA for 30 min prior to lysis.
Equal aliquots of lysates were immunoprecipitated
with anti-FLAG mAb and immune complexes were
analyzed for b-COP by immunoblotting.
(D) Membrane (P, 100,0003 g pellet) and cytosolic
(S, 100,000 3 g supernatant) fractions (left panel)
were prepared from post-nuclear supernatants
(PNS, right panel) of control (Ctrl siRNA) or GIV-
depleted (GIV siRNA) COS7 cells and analyzed for
the indicated proteins by immunoblotting.
(E) Bar graphs display the relative abundance
of b-COP in membrane fractions in (D), derived
from the equation [(P) / (S + P)] 3 100. Data were
normalized to control and expressed as %
changes. Results are expressed as mean ± SEM.
(F) GIV-depleted cells were treated with adenovirus
containing RNAi-resistant GIV-WT or GIV-FA. Ho-
mogenates of these cells were used to prepare
membrane and cytosolic fractions as in (D) and
analyzed by immunoblotting.
(G) Bar graphs display the relative abundance of
b-COP in membrane fractions in (F).
(H) Control (Ctrl siRNA) or GIV-depleted (GIV siRNA)
HeLa cells were prepermeabilized with 0.1%
Saponin (to release cytosolic b-COP), stained for
b-COP (green) and the nucleus (DAPI, blue), and
analyzed by confocal microscopy. The scale bar
represents 10 mm.
(I) Bar graphs display the number of COPI vesicles
per cell in (H), as determined by 3D-reconstruction
using Imaris software (n = 3; mean ± SEM; >20
cells/experiment).
(J) Bar graphs display the number of COPI vesicles
in adeno-GIV-WT-HA or -GIV-FA-HA infected cells
(see Figure S2F) that were analyzed exactly as in
(H and I) (n = 3; mean ± SEM; >10 cells/experiment/
condition).
(K) Whole cell lysates (WCL) of control (Scr shRNA)
or GIV-depleted (GIV shRNA) cells were subjected
to differential centrifugation to obtain a 15,000 3 g
(P2) fraction enriched in Golgi membranes, a 100,0003 g (P3) fraction containing COPI vesicles, and a cytosolic fraction (S, 100,0003 g supernatant). Fractions
were analyzed for GIV, b-COP, and GM130 (Golgi marker) by immunoblotting.
(L) Bar graphs display the quantification of b-COP in P3 fractions normalized to WCL. Increased membrane-association of b-COP as determined by membrane-
cytosol fractionation or increased peripheral vesicular staining of b-COPwe observe inGIV-depleted cells (D, E, H, and I) or in cells expressingGIV-FA (F, G, and J)
is not due to changes in absolute cellular levels of b-COP (see Figures S2G and S2H).ERGIC-53, an ER/Golgi intermediate compartment marker pro-
tein (Figures 3A and S3B). By contrast, in GIV-depleted cells,
numerous punctate b-COP-stained vesicles were seen in the
cell periphery (Figure S3A), frequently colocalizing with or in192 Developmental Cell 33, 189–203, April 20, 2015 ª2015 Elsevier Iclose proximity to clusters of tubulo-vesicular ERGIC structures
(Figures 3A and S3B). Because such colocalization was previ-
ously reported (Saitoh et al., 2009) in cells with higher levels of
active Arf1, these results suggest that depletion of GIV ornc.
Figure 3. Activation of Gai by GIV Terminates
Arf1 Signaling
(A) Depletion of GIV promotes accumulation of
COPI vesicles in the ER-Golgi intermediate
compartment (ERGIC). Left, control (Ctrl siRNA,
upper panel) or GIV-depleted (GIV siRNA, lower
panel). HeLa cells were fixed and stained for b-COP
(red) and ERGIC-53 (green). Merged panels display
the overlay of b-COP (red) and ERGIC-53 (green)
panels. Insets on merge panels viewed at higher
magnification show limited colocalization of
ERGIC-53 with b-COP in the cis-Golgi in control
cells and that ERGIC-53 is also found in vesicles
scattered throughout the cytoplasm, which do
not stain for b-COP. In GIV-depleted cells there
is increased colocalization between b-COP and
ERGIC-53 and these vesicular structures that cos-
tain for both b-COP and ERGIC-53 are more
dispersed. The white line in the insets indicates the
pixels used for the red green blue (RGB) profile
plots shown (see Experimental Procedures). The
scale bar represents 10 mm. Right, RGB profiles of
ERGIC-53 (green) and b-COP (red) corresponding
to lines in merge of (A) as shown in insets.
(B) COS7 cells were treated with control (-) or GIV
siRNA (+) and adenoviral vectors expressing
siRNA-resistant GIV-WT or GIV-FA as indicated.
Equal aliquots of lysates (bottom panels, 5% input)
were analyzed for Arf1,GTP by carrying out GST
pull-down assays with GST-GGA3. Bound proteins
(top panel) were analyzed for active Arf1 by immu-
noblotting.
(C) Bar graph displays the band densitometry
quantification of Arf1,GTP (bound)/total Arf1 (in-
puts) in (B). Data were normalized to control and
expressed as%changes. Results are expressed as
mean ± SEM.
(D) COS7 cells expressing Gai3-WT, Gai3-WF
mutant, or control vector were analyzed for levels of
Arf1,GTP as in (B).
(E) Bar graph displays the band densitometry
quantification of Arf1,GTP (bound)/total Arf1 (in-
puts) in (D). Results are expressed as mean ± SEM.inhibition of GIV’s GEF activity may perturb uncoating of COPI
vesicles via an underlying fundamental defect in the regulation
of Arf1.
GIV Suppresses the Levels of Arf1,GTP via Its Ability to
Activate Gai
To determine if GIV or its GEF function modulate Arf1 activity in
cells, we used the previously validated pull-down assay with a
GST-GAT domain of GGA3, which selectively binds the
active GTP-bound pool of Arf1 (Cohen and Donaldson,
2010). We found that compared to control cells, the levels
of Arf1,GTP were increased 60% in GIV-depleted cells
(Figures 3B and 3C). This increase was effectively reversed
to normal levels by the expression of siRNA-resistant hemag-
glutinin (HA)-tagged GIV-WT, but not by the GEF deficient
GIV-FA mutant (Figures 3B and 3C). These findings indicate
that GIV is required for downregulation of Arf1,GTP, and that
GIV’s GEF function (which activates Gai) is required for this
effect.DeveTo confirm that activation of Gai3 by GIV regulates the levels of
active Arf1, we transfected cells with WT Gai3 or the W258F
mutant of Gai3 that cannot be activated by GIV and assessed
the level of Arf1,GTP. We found that Arf1,GTP was increased
by 70% in the cells expressing Gai3-W258F compared to
Gai3-WT (Figures 3D and 3E), indicating that activation of Gai3
by GIV is essential for downregulation of Arf1 signaling, and
that inhibition of the GIV-Gai axis results in increased active Arf1.
GIV and Its GEF Function Regulate ER-Golgi Vesicle
Transport
To determine if accumulation of COPI vesicles and increased
active Arf1 in GIV-depleted cells also affects protein trafficking
along the secretory pathway, we examined the transport of
vesicular stomatitis virus G protein (VSVG) from the ER to the
PM using the well-characterized GFP-tagged VSVG-tsO45
mutant. This mutant VSVG is retained in the ER at 40C and
moves out of the ER and passes through the Golgi to the PM
when shifted to 32C (Gallione and Rose, 1985). Surfacelopmental Cell 33, 189–203, April 20, 2015 ª2015 Elsevier Inc. 193
Figure 4. GIV and Its GEF Function Are Required for ER-Golgi Vesicle Transport and Integrity of the Golgi Structure
(A) Control (Ctrl siRNA) or GIV-depleted (GIV siRNA) COS7 cells were transfected with VSVG-tsO45-GFP and incubated at 40C overnight before shifting to 32C
for the indicated times. Cell surface proteins were labeledwithmembrane-impermeable Sulfo-NHS-SS-Biotin as described in Supplemental Information. Surface
biotinylated and total VSVG-GFP were analyzed by immunoblotting with anti-GFP.
(B) Graph displays the quantification of VSVG trafficking in control or GIV-depleted cells expressed as surface biotinylated to total VSVG-GFP, as determined by
band densitometry. Data were normalized to control and expressed as % changes. (n = 3; error bars = SEM).
(C) Graph displays the quantification of VSVG trafficking (see Figure S4A) in cells expressing GIV-WT or GIV-FA calculated as in (B) (n = 4; error bars = SEM).
(D) Control (Ctrl siRNA) and GIV-depleted (GIV siRNA) HeLa cells transfected with myc-cochlin were pulsed with [35S]Met-Cys (100millicurie, 1/1,000 of a curie, a
non-SI unit of radioactivity/ml) for 30 min, washed, and chased for the indicated times prior to lysis. Equal aliquots of media and cell lysates were immuno-
precipitated with anti-myc mAb and analyzed for [35S]-labeled-cochlin by autoradiography.
(E) Graph displays the quantification of results in (D), as determined by band densitometry and expressed as%myc-cochlin secreted in media/total myc-cochlin
in lysates (n = 5).
(F) Graph displays the quantification ofmyc-cochlin secretion fromHeLa cells stably expressing GIV-WT or GIV-FA (see Figure S4B) expressed as%myc-cochlin
secreted in media/total myc-cochlin in lysates (n = 5).
(legend continued on next page)
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biotinylation assays showed that compared to controls, in GIV-
depleted cells the amount of VSVG that reached the PM at 30
and 60 min was reduced by 40% and 30%, respectively (Fig-
ures 4A and 4B), indicating a delay in protein transport to the
PM. Similarly, compared to cells expressing GIV-WT, VSVG traf-
ficking to the PM was delayed in cells expressing GIV-FA (Fig-
ures 4C and S4A), indicating that GIV’s GEF function is essential
for GIV’s role in VSVG trafficking. Release of myc-cochlin, a
secretory protein, was also found to be delayed in GIV-depleted
cells (Figures 4D and 4E) and in those expressing GIV-FA (Fig-
ures 4F and S4B). These results indicate that GIV is required
for trafficking of two different cargo proteins in the secretory
pathway, VSVG (a membrane protein) and myc-cochlin (a solu-
ble protein), and that the GEF function is essential for GIV’s
role in regulation of such traffic.
Because COPI has been implicated in anterograde and retro-
grade traffic between the Golgi and the ER (Orci et al., 1997;
Scheel et al., 1997), next we determined whether GIV depletion
affects anterograde transport. We assessed the amount of
VSVG that trafficked from ER to the Golgi, as determined by
the degree of colocalization with the Golgi marker Man II at
32C after 30 min. In controls, considerable VSVG accumulated
in the Golgi within 5 min and was rapidly concentrated at the
Golgi during subsequent time points. In GIV depleted cells (Fig-
ure S4C) or in cells expressing the GIV-insensitive Gai3-WF
mutant (Figure S4D), the amount of VSVG found in the Golgi
was decreased at all time points (by 35% at 30 min; Fig-
ure S4C). These findings indicate that both depletion of GIV
and selective inhibition of GIV’s ability to activate Gai3 delays
protein transport from the ER to the Golgi. Another strategy to
assess the transport of VSVG-tsO45 from ER to Golgi is to detect
acquisition of resistance to Endoglycosidase H (Endo-H) diges-
tion of VSVG (Balch et al., 1986). When control cells were incu-
bated at 40C for 16 hr and then shifted to 32C for 0–120 min,
VSVG starts to acquire Endo-H-resistance by 30 min and the
major pool of VGV-G acquires resistance by 120 min. In cells
depleted of GIV, VSVG remains mostly sensitive to Endo-H at
all points, indicative of a delay in VSVG trafficking from the ER
to the early Golgi (Figures 4G and 4H). Furthermore, a majority
of VSVG acquired Endo-H-resistance by 120 min in COS7 cells
overexpressing GIV-WT, whereas VSVG remained sensitive to
Endo-H in cells expressing inactive GIV-FA under the same
conditions (Figures 4I and S4E), demonstrating that GIV’s GEF(G) Control (Ctrl siRNA) or GIV-depleted (GIV siRNA) COS7 cells were infected wit
Cells were then shifted to 32C for the indicated period of time prior to lysis. Equal
for Endo-H-resistance (upward shift, upper panel) and GIV depletion (lower pane
(H) Graph displays the quantification of the data presented in (G), expressed as the
VGVG (VSVGs; lower band) at various time points (n = 4).
(I) Graph displays the ratio between Endo-H-resistant versus sensitive VGVG in
(J) Control (Ctrl siRNA) or GIV-depleted (GIV siRNA) COS7 cells transfected with c
to 40C (to allow transport of the chimeric receptor to the ER) for the indicated tim
(K) Bar graph displays the % of the total tsO45-VSVG-KDELr-Myc within the Golg
Information for details) (n = 3; five cells/experiment).
(L) Control (Ctrl siRNA) or GIV-depleted (GIV siRNA) COS7 cells were fixed an
microscopy. Representative images of control or GIV-depleted cells are shown
represents 10 mm.
(M) Quantitative analysis of the Golgi phenotype in control and GIV-depleted cell
images, and objects were measured using the Analyze Particles function. Bar gr
cells/experiment).
Devefunction is essential for normal protein trafficking in the antero-
grade pathway.
To assess COPI-dependent retrograde trafficking, we
analyzed the redistribution of a chimeric VSVG-tsO45-KDEL
receptor (KDELr) from the Golgi to the ER by immunofluores-
cence (Cole et al., 1998). At 32C this chimera accumulates in
the cis-Golgi, and upon shifting the cells to 40C, it redistributes
to the ER via the retrograde pathway. In controls, the chimera
had redistributed to the ER by 60 min at 40C. However, in
GIV-depleted cells, redistribution was substantially delayed,
after 60 min the chimera was still present in ERGIC and the
Golgi, as well as the ER (Figure 4J). The ratio of Golgi-associated
to total VSVG-tsO45-KDELr fluorescence was 2.2-fold higher
in GIV-depleted cells than in controls at 30 min (Figure 4K).
These results indicate that GIV is essential for both anterograde
and retrograde COPI-mediated transport between the ER and
Golgi.
GIV and Its GEF Function Maintain Golgi Ribbon
Organization
Because Arf1 not only regulates vesicle transport, but also main-
tains Golgi structure (Dascher and Balch, 1994), we investigated
if increased levels of active Arf1 in GIV-depleted cells also affect
the structure of the Golgi. Staining for the cis- and medial-Golgi
markers Man II (Figure 4L) and GM130 or the trans-Golgi marker
GalT (Figure S4F) revealed that, as anticipated, the Golgi was
compact and juxtanuclear in position in control cells. By
contrast, in GIV-depleted cells, the Golgi stacks were unlinked
and Golgi fluorescence was distributed across a larger number
of structures (80% increase; Figure 4M), although the total
Golgi fluorescence was comparable to that in controls. Electron
microscopy revealed that compared with control cells, the Golgi
cisternae were reorganized into smaller, mini-stacks distributed
over a broader area in GIV-depleted cells (Figure S4I). The Golgi
was also dispersed in cells expressing either the GEF-deficient
GIV-FA (Figure S4G) or GIV-insensitive Gai3-WF (Figure S4H)
mutants that cannot assemble a functional GIV-Gai complex,
indicating that GIV’s ability to bind and activate the G protein is
required for the integrity of Golgi stacks. These findings show
that increased Arf1 activity in cells without a functional GIV-
GEF is associated with aberrations in two fundamental pro-
cesses regulated by Arf1; i.e., Golgi structure and function
(vesicle trafficking).h VSVG-tsO45 retrovirus for 1 hr at 32C and shifted to 40C for the next 16 hr.
aliquots of lysates were incubated with Endo-H (+) and subsequently analyzed
l) by immunoblotting using anti-VSVG and anti-GIV, respectively.
ratio between Endo-H-resistant (VSVGr; upper band) versus Endo-H-sensitive
cells expressing GIV-WT or GIV-FA (n = 3) (see Figure S4E).
himeric tsO45-VSVG-KDELr-Myc were first incubated at 32C and then shifted
es, fixed, and stained for myc (white pixels). The scale bar represents 10 mm.
i region, quantified from confocal images of cells at 30 min (see Supplemental
d stained for Man II (red) and nuclei (DAPI; blue) and analyzed by confocal
with a magnified view of the boxed area enlarged to the right. The scale bar
s by Image J (NIH) are shown (left panels). A fixed threshold was applied to all
aphs (right) display the average number of Golgi elements per cell (n = 3; >14
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Figure 5. GIV Terminates Arf1 by Targeting ArfGAP3 to COPI Vesicles and Releasing Free Gbg Dimers
(A) Lysates of COS7 cells coexpressing pCEFL-GST-GIV or GST alone (pCEFL-GST) and either ArfGAP1-myc (lanes 1 and 4) or ArfGAP3-myc (lanes 2 and 5) were
incubated with glutathione-sepharose beads and bound proteins were analyzed by immmunoblotting.
(B) COS7 cells cotransfected with b-GalT-YFP (Golgi marker) and either ArfGAP1-Myc or ArfGAP3-Myc were analyzed for interaction between GIV and ArfGAPs
by in situ PLA using rabbit anti-GIV andmouse-anti-myc antibodies. Similar distribution and expression of ArfGAPs 1 and 3 were verified by immunofluorescence
(see Figure S5C). Incubation with primary antibodies was excluded for negative controls. Red dots = sites of interaction. The scale bar represents 10 mm.
(C) Immunoprecipitation was carried out on lysates from control (-) or GIV-depleted (GIV siRNA +) cells expressing ArfGAP3-myc using the CM1A10 (anti-
coatomer) antibody. Inputs and immunoprecipitates were analyzed by immunoblotting. Band densitometry confirmed a 60% reduction in ArfGAP3 in immune
complexes from GIV-depleted cells.
(legend continued on next page)
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GIVRegulates Arf1 via Its Ability to BindArfGAPs 2/3 and
by Releasing Gbg
Next, we explored how GIV suppresses Arf1 activity and
explored GIV’s interactions with the regulatory network of
ArfGAP proteins (Weimer et al., 2008) that maintain finiteness
of Arf1 signaling at the Golgi and on COPI vesicles. There are
three Golgi-associated ArfGAPs which function in the COPI
system, but at two distinct steps in vesicular transport. ArfGAP1
is assumed to drive the cycle of activation and inactivation of
Arf1, and ArfGAP2 and ArfGAP3 are believed to regulate
uncoating (Beck et al., 2009; Shiba and Randazzo, 2012). We
reasoned that GIV might regulate Arf1,GTP at the step of
uncoating through ArfGAPs 2/3. We found that GIV specifically
bound ArfGAP2/3, but not ArfGAP1 in pull-down assays (Figures
5A and S5A). Such specificity was also confirmed by in situ PLA
studies, numerous sites of GIV-ArfGAP interactions were seen in
cells expressing ArfGAP3-Myc, but no such interactions were
observed in cells expressing ArfGAP1-Myc (Figure 5B).
Next, we investigated whether GIV affects the association of
ArfGAP3 with COPI-coated membranes. Immunoprecipitation
was carried out with anti-CM1A10 IgG from lysates of control
and GIV-depleted cells expressing ArfGAP3-Myc. Interaction
of ArfGAP3-Myc with coatomer was greatly reduced in GIV-
depleted cells (Figure 5C) despite the abundance of b-COP on
membranes (Figures 2D and 2E). In situ PLA studies confirmed
that depletion of GIV was associated with a 60% reduction in
the number of sites of interaction between ArfGAP3-Myc and
coatomer (Figures 5D, 5E, and S5B). A similar reduction was
also observed in Golgi localization of ArfGAP3, but not ArfGAP1
in GIV-depleted cells by immunofluorescence (Figure S5C).
These results demonstrate that GIV is required for the associa-
tion of ArfGAP3 with COPI vesicles and Golgi membranes, and
that failure of such association in GIV-depleted cells may
contribute, in part, to the elevated levels of Arf1,GTP and accu-
mulation of COPI vesicles we observe in these cells. Because
GIV also binds ArfGAP2 (Figure S5A), which shares a high degree
of sequence identity with ArfGAP3 (Frigerio et al., 2007) and
complements the functions of ArfGAP3 (Weimer et al., 2008), it
is likely that GIV affects the localization and activation of both
ArfGAPs 2 and 3.
Because GIV’s ability to affect Arf1 activity is also dependent
on its ability to activate Gai, next we asked how GIV may link
trimeric G protein signaling to the regulation of Arf activity. Prior
work has implicated ‘‘free’’ Gbg subunits of G proteins as inhib-
itors of Arf1 activity on Golgi membranes (Donaldson et al.,
1991). We asked if inhibition of Arf1,GTP by GIV-GEF is a conse-
quence of release of Gbg upon Gi activation. To investigate this,
we used a well-characterized peptide corresponding to the C
terminus of the b-adrenergic receptor kinase (bARK-CT) that
sequesters Gbg. Consistent with the role of Gbg in downregula-
tion of Arf1 activity, sequestration of Gbg in COS7 cells trans-
fected with bARK-CT was associated with an elevation of(D) Control (Ctrl siRNA) or GIV-depleted (GIV siRNA) COS7 cells cotransfected w
between b-COP and ArfGAP3-Myc by in situ PLA. Incubation with primary antibod
bar represents 10 mm. Depletion of GIV and equal transfection of ArfGAP3-Myc
(E) Bar graphs display the quantification of interactions (n = 3; >20 cells/experim
(F) Lysates of COS7 cells expressing GIV-WT, bARK-CT, and control vector (-) w
(G) Bar graphs display the quantification of the data in (F), expressed as the ratio
DeveArf1,GTP levels (Figures 5F and 5G). Suppression of Arf1 activity
in cells overexpressing GIV-WT was reversed when bARK-CT
was coexpressed with GIV-WT. Noteworthy, the levels of Arf1
activity in cells coexpressing bARK-CT and GIV-WT were inter-
mediate between the high levels of activity in cells expressing
bARK-CT alone and the low levels of activity in cells expressing
GIV-WT alone, indicating that bARK-CT and GIV-WT antagonis-
tically modulate Arf1 activity, presumably via their ability to
sequester or release, respectively, free Gbg subunits. Further-
more, sequestration of free Gbg subunits by bARK-CT delayed
VSVG trafficking to the PM (Figure S5D) and dispersed the Golgi
ribbon structure (Figure S5E). Noteworthy, these phenotypes
resemble that of cells in which GIV-dependent activation of Gi
and subsequent release of free Gbg is impaired (by expressing
either a GEF-deficient GIV-FA mutant or a GIV-insensitive
Gai3-WF mutant; Figures 4 and S4). These data demonstrate
that the availability of free Gbg is critical for termination of Arf1
activity and for the functional and structural integrity of the Golgi;
either sequestration (by bARK-CT) or impaired release of Gbg
(absence of a functional GIV-GEF) leads to enhanced Arf1 activ-
ity. Taken together, our findings indicate that GIV suppresses the
levels of active Arf1 and regulates ER-Golgi transport and Golgi
structure in part via activation of Gi and release of free Gbg.
GIV Binds Active Arf1
Next, we explored what event might trigger GIV-dependent
termination of Arf1 activity and vesicle uncoating. We hypothe-
sized that targeting of GIV to membranes with active Arf1 could
be one such event that sets off negative feedback loops allowing
GIV to subsequently terminate Arf1 signaling. Because active
Arf1 regulates membrane association of several proteins
involved in vesicle trafficking (Donaldson and Jackson, 2011),
we asked whether Arf1 also affects the membrane association
of GIV. We found that membrane-associated GIV was increased
by 30% in cells expressing the constitutively active Arf1
mutant, Arf1[Q71L], compared to those expressing the
dominant-negative mutant, Arf1[T31N] (Figures 6A and 6B). By
immunofluorescence, we confirmed Golgi membranes as the
major site for Arf1-dependent recruitment of GIV, where both
proteins colocalized (Figures 6C and S6A). When we carried
out immunoprecipitation assays from lysates of human embry-
onic kidney (HEK)293 cells coexpressing Arf1-HA and GIV-
FLAG, we found that Arf1 coimmunoprecipitates with GIV
(Figure 6D). When recombinant myristoylated Arf1 was loaded
with guanosine diphosphate (GDP) (inactive conformation) or
Guanosine 50-[b,gamma-imido]triphosphate (50-Guanylyl-imido-
diphosphate trisodium salt hydrate [GMP-PNP], tomimick active
conformation) and incubated with purified GST-GIV or GST
alone, Arf1 loaded with GMP-PNP, but not GDP specifically
bound to GIV (Figure 6E), indicating that the Arf1-GIV interaction
is direct and that GIV preferentially binds active Arf1. Together,
these data show that GIV binds active Arf1 and that activationith b-GalT-YFP (Golgi marker) and ArfGAP3-Myc were analyzed for interaction
ies was excluded for negative controls. Red dot = sites of interaction. The scale
were confirmed by IB (inset).
ent) in (D).
ere analyzed for Arf1,GTP using GST pull-down assays as in Figure 3B.
of Arf1,GTP to total Arf1. Results were presented as mean ± SEM (n = 5).
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Figure 6. Active Arf1 Binds GIV and Triggers Its Membrane Association
(A) Membrane-cytosol fractionations were carried out on COS7 cells expressing HA-tagged WT, constitutively active (Q71L), or dominant-negative (T31N) Arf1,
and fractions were analyzed for GIV and b-COP as in Figure 2D.
(B) Bar graph displays the % GIV in membrane (P) fractions derived from (P)/(S + P) 3 100. Results are expressed as mean ± SEM.
(C) COS7 cells transfected with HA-tagged WT Arf1 or Arf1[Q71L] mutant were fixed and stained for Arf1 (HA; green), GIV (red), and nuclei (DAPI; blue). Panels
on the left show an overlay of all three stains (see Figure S6A for individual stains), whereas panels on the right display the red pixels in grayscale, which
represent GIV.
(D) Immunoprecipitation was carried out from lysates of HEK293T cells expressing Arf1-HA alone or Arf1-HA and GIV-FLAG using anti-FLAG mAb, and bound
immune complexes were analyzed for Arf (HA) and GIV by immunoblotting.
(E) Purified myristoylated Arf1 preloaded with GDP or GMP-PNP was incubated with GST or GST-GIV (expressed and purified from HEK293T cells) immobilized
on glutathione beads. Bound proteins were analyzed for Arf1 and GIV by immunoblotting.
(F) Lysates of HEK293T cells coexpressing HA-tagged Arf1[Q71L] and GST or GST-tagged GIV constructs (GIV-NT, 1–220 aa; GIV-CT, 1,660–1,870 aa; GIV-fl,
1–1,870 aa) were incubated with glutathione beads. Bound proteins were analyzed for Arf1 and GST proteins by immunoblotting.
(legend continued on next page)
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of Arf1 enhances recruitment of GIV on Golgi membranes and
may initiate/trigger the interaction between GIV and COPI-
coated membranes we observe (see Figure 2).
To determine how GIV binds Arf1, we carried out protein inter-
action assays with different GST-tagged domains of GIV and
found that the N-terminal 200 amino acids (aa) of GIV, the
Hook domain, is sufficient to interact with constitutively active
Arf1[Q71L] (Figure 6F). A sequence alignment between GIV’s
Hook domain and the GAT domain of the GGA family of proteins,
which binds active Arf1, revealed a striking similarity in sequence
(Figure 6G). Three critical leucines that have been previously
implicated in mediating the interaction between Arf1,GTP and
a Hook-like patch on the GGA-GAT domain (Collins et al.,
2003; Shiba et al., 2003) are evolutionarily conserved in GIV (Fig-
ures 6G and S6B). A homology model of this region generated
using the previously solved crystal structure of the GGA-GAT
domain (Shiba et al., 2003) revealed a helix-loop-helix conforma-
tion much like that assumed by the Hook-like patch within the
GGA-GAT domain (Figure 6H). Using the available structure of
the Arf1,GTP:GGA1-GAT complex as a template (Protein Data
Bank [PDB] 1J2J), we modeled the Arf1,GTP:GIV interface and
found that key residues that were conserved between GGA
and GIV are required to form the Arf1,GIV interface (Figure 6I).
Using pull-down assays with active Arf1[Q71L] mutant and the
GST-tagged Hook domain of GIV, we confirmed that mutation
of the key residues disrupted Arf1,GIV interaction as predicted
(Figure 6J), thereby validating the homology model (Figure 6I).
These results demonstrate that GIV preferentially binds active
Arf1 in a manner identical to GGA proteins and, thereby, serves
as an effector of active Arf1 at the Golgi.
Conclusions
These studies identify GIV as a bona fide activator of heterotri-
meric G proteins at the Golgi and as a platform for crosstalk be-
tween trimeric G proteins and themonomeric GTPase Arf1. Such
crosstalk via GIV regulates both vesicle trafficking and the orga-
nization of Golgi stacks. Our results provide mechanistic insights
into how GIV orchestrates a two-pronged mechanism to sup-
press Arf1 signaling when COPI vesicles carrying cargo proteins
from the ER/ERGIC dock on the Golgi membranes (see Figure 7),
first, activation of Gai by GIV at the Golgi complex releases free
Gbg, which in turn inhibits Arf1 signaling. Second, GIV interacts
with both b-COP and ArfGAP2/3 and facilitates the recruitment(G) Sequence alignment of GIV with GGA proteins reveals a putative GGA-GAT l
N-terminal Hook domain of human GIV (BAE44387, 90–150 aa) was aligned w
residues are shaded in black; similar residues in gray. This alignment reveals that t
The residues marked with red star were mutated in this work to confirm that the
(H) 3D model of 90–150 aa within GIV’s Hook domain (purple) superimposed on
protein (green), generated based on the alignment in (G). Key residues in GGA tha
are labeled.
(I) 3D model of a complex between Arf1,GTP (colored by blue/green/yellow/red
(dark red). GTP and anMg ion are shown as colored sticks and a blue sphere, resp
residues inGIV. The right panel shows themost important interface residues in Arf1
isoleucine at 49, glycine at 50) and also involves b2/3-strands (blue, containing
Residues L94, I98, I106, and F113 form the core of the hydrophobic patch on GIV
Multiple polar contacts surrounding this patch may additionally strengthen the A
(J) Lysates of HEK293T cells coexpressing HA-tagged Arf1[Q71L] and WT or mu
incubated with glutathione beads. Bound proteins were analyzed for Arf1 and G
mutant GIV-NT proteins bound tubulin.
Deveof the coat-dependent GAP protein onto theGolgi andCOPI ves-
icles. Once recruited, the catalytic activity of ArfGAP2/3 is
enhanced, presumably at/near the target Golgi membranes,
and consequently Arf1 signaling is efficiently terminated and
COPI vesicles uncoat prior to fusion.
The first event; i.e., activation of Gi by GIV and release of Gbg
(GIV/Gbg pathway) on Golgi membranes, is a hierarchically
dominant step because without a functional GEF motif in GIV,
ArfGAP3 localized to Golgi/COPI vesicles normally (Figure S7A),
but Arf1 activity remained elevated, vesicle uncoating was
impaired, trafficking was delayed, and Golgi ribbons were
dispersed. Activation of Gi and release of free Gbg dimers is
also a central mechanism by which GIV terminates Arf1 at/near
acceptor (i.e., Golgi) membranes and is consistent with prior
work demonstrating the inhibitory role of Gbg in Arf signaling
(Cohen and Donaldson, 2010; Colombo et al., 1995). Although
hierarchically dominant, the GIV/Gbg pathway is dependent
on the GIV/ArfGAP2/3 pathway, because the ability of
GIV-GEF to downregulate Arf1 activity is abolished in cells
without ArfGAP3 (Figure S7B). These findings suggest that the
GIV/Gbg and the GIV/ArfGAP2/3 pathways work in-tandem
and/or synergize with each other to terminate Arf1 signaling
and complete uncoating of vesicles tethered to Golgi mem-
branes. Such synergy on Golgi membranes may impart direc-
tionality to anterograde ER-Golgi transport.
As to what upstream event sets off the GIV/Gbg and the
GIV/ArfGAP2/3 pathways, which culminate in termination of
Arf1 signaling, we show that recruitment of GIV to membranes
by direct binding to active Arf1 could be the likely trigger. Based
on its ability to bind Arf1,GTP and PI(4)P (Figure 7; see Enomoto
et al., 2005), GIV joins the handful of PI(4)P effectors whose
recruitment to the Golgi also requires activated Arf1 (Mayinger,
2011). Such dual recognition is believed to function in a
‘‘coincidence-detection’’ mechanism that provides additional
specificity to achieve restricted localizations on membrane
microdomains (Carlton and Cullen, 2005). We propose that GIV
is recruited specifically to the membrane microdomains that
have active Arf1 to impose finiteness to Arf1 signaling, trigger
uncoating of COPI vesicles, and thereby affect the anterograde
trafficking of secreted and membrane proteins along the exo-
cytic pathway, all via a network of hierarchical functional interac-
tions, mediated by distinct modules (Figure 7, upper panel). The
abnormalities we observe in retrograde trafficking could eitherike region within the Hook domain of GIV. The sequence corresponding to the
ith the sequence of human GGA1/2 proteins using CLUSTAL W. Conserved
he key aa that are essential for Arf1,GGA-GAT interaction are conserved in GIV.
y are essential for the Arf1:GIV interaction.
the solved structure of the Hook-like patch on GAT domains of human GGA1
t are important for coupling to Arf1,GTP and the corresponding residues in GIV
rainbow from N to C terminus) and the N-terminal helix-loop-helix motif of GIV
ectively. Left panel shows the overall complex with themost important interface
. The binding occurs at the loosely helical Arf1 loop ‘‘switch 1’’ (blue, containing
F51 and W66) and the second alpha helix (green, containing H80 and Y81).
’s helix-loop-helix motif that interacts with residues F51, W66, and Y81 in Arf1.
rf1,GTP:GIV interaction and provide specificity.
tant GST-tagged GIV-NT 1–220 aa constructs (L94D, I98D, and L106D) were
ST proteins by immunoblotting. As expected for a Hook domain, WT, and all
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Figure 7. Summary and Working Model
(Upper), schematic of the multi-modular GIV pro-
tein is shown. A patch of residues within the
N-terminal Hook-domain of GIV (purple) resembles
the Hook-like patch within the GAT domain of
GGA1/2/3 proteins and directly binds GTP-bound
Arf1. The coiled-coil domain (blue) assists in ho-
mooligomerization, whereas the PI(4)P-binding
domain mediates binding to phosphoinositides at
the Golgi and the PM (Enomoto et al., 2005). The
C-terminally located GEF motif (red) of GIV binds
and activates GaI, and releases free Gbg. Homol-
ogy models shown for Arf1:GIV-Hook (left) is vali-
dated in current work (Figure 6) and that for Gai3
(green):GIV-GEF (red) was validated previously
(right; see Garcia-Marcos et al., 2009). (Middle),
schematic of perinuclear Golgi compartment is
shown. GIV is a GEF for Gai that activates trimeric
G proteins on Golgi membranes and releases free
Gbg dimers. (Lower), schematic of hierarchical
steps that enable GIV to terminate Arf1 signaling
and trigger COPI coatomer dissociation during
anterograte trafficking. From left to right, mem-
brane-associated Arf1,GTP recruits COPI coat-
omer (represented here as b-COP) onto mem-
branes and promotes vesicle budding from the ER/
ERGIC compartment. GIV is recruited to COPI
vesicles, presumably as an effector of active Arf1,
and further stabilized by its ability to interact with
the coat protein, b-COP. Once on vesicles, GIV
binds and recruits ArfGAP3, which is required for
terminating Arf1 activity and initiating the process
of uncoating (STEP 1). Termination of Arf1 activity
is further perpetuated by a second step (STEP 2),
which involves activation of Gi and release of free
Gbg by GIV on Golgi membranes. This second step
presumably takes place only when COPI vesicles
dock on Golgi membranes (i.e., acceptor mem-
brane) and serves to terminate any remaining
active Arf1 on those vesicles via pathway(s) that
remain unclear (‘‘’’?) and ensure completion of the
uncoating process just prior to vesicle fusion.be a direct or an indirect consequence of delayed anterograde
trafficking, as the two processes are interdependent (Reilly
et al., 2001). We showed that modulation of Arf1 signaling by
GIV also maintains Golgi structure, and in the absence of GIV,
Golgi stacks are reorganized into unlinked mini-stacks scattered
over a larger area. Thus, our findings reveal the fundamental
molecular mechanisms behind the previously observed roles of
G proteins at the Golgi; e.g., membrane trafficking (Simpson
et al., 2012), vesicle fusion, (Helms et al., 1998), and in the main-
tenance of Golgi structure (Saini et al., 2010). BecauseGproteins
and the other essential components (Arf1, ArfGAP3, andGIV) are
also present on other membranes, it is possible that the funda-
mental mechanisms we define here also facilitate vesicular traf-
ficking from the trans-Golgi network (TGN) to the PM and/or
endolysosomal system, as shown in the case of ArfGAP3 (Shiba
et al., 2013).
With regard to ArfGAPs, our finding that GIV selectively binds
and localizes ArfGAP2/3 (but not ArfGAP1) to COPI vesicles to
trigger vesicle uncoating are consistent with the fact that
ArfGAP1 triggers vesicle formation (Cole et al., 1998; Shiba
and Randazzo, 2012), whereas ArfGAPs 2/3 trigger uncoating200 Developmental Cell 33, 189–203, April 20, 2015 ª2015 Elsevier I(Shiba and Randazzo, 2012). Although ArfGAP3 is reported to
be a coat protein-dependent ArfGAP (Schindler et al., 2009;
Weimer et al., 2008), i.e., both its association with COPI vesicles
and its GAP activity are triggered by coat proteins (Kliouchnikov
et al., 2009), b-COP, the major coat-protein on COPI vesicles
does not fulfil such a role (Weimer et al., 2008). It is thus possible
that GIV serves as the long-sought coatomer-associated
cofactor for ArfGAP3. We conclude that GIV’s ability to bind
and localize ArfGAP3 to COPI vesicles is one arm of the
two-pronged mechanism that enables GIV to terminate Arf1
signaling and trigger vesicle uncoating; whether the other arm,
i.e., GIV/Gbg pathway, directly enhances the catalytic activity
of ArfGAP3 on the membranes remains to be determined.
Finally, we show that the multi-modular make-up of GIV en-
ables it to serve as a platform for crosstalk between heterotri-
meric G proteins and monomeric Arf G proteins (Figure 7, top
panel). The paradigm of dual regulation of monomeric and
trimeric G proteins by a single protein has been previously
demonstrated in only a handful of proteins and is exemplified
by p115RhoGEF (Kozasa et al., 1998). However, GIV serves as
the only molecule to date that links trimeric G protein signalingnc.
on membranes to inactivation of Arf1, and thereby, acts as an
intermediary in the regulation of Arf proteins by G proteins.
Because full-length GIV is evolutionarily young (i.e., found only
in higher eukaryotes like birds and mammals) (Ghosh et al.,
2011), coupling of trimeric G protein signaling with monomeric
Arf G proteins by GIV likely represents an evolutionary improve-
ment to meet the demands of increasingly complex trafficking
itineraries in higher eukaryotes. Finally, that GIV localizes
also at the PM and modulates pro-migratory and mitogenic
growth factor signals via activation of Gai raises the possibility
that the previously observed crosstalk between growth
factor signals initiated at the PM and functions of the Golgi
(Blagoveshchenskaya et al., 2008; Weller et al., 2010) may be
orchestrated in part via the GIV platform. Such crosstalk may
coordinately trigger secretion in response to pro-migratory sig-
nals when the GIV-GEF is activated and/or coordinate the
dispersal of Golgi in response to mitogenic signals when the
GIV-GEF is disabled. Thus, the crosstalk GIV sets up between
trimeric G proteins and monomeric Arf G proteins at two
locations within the cell may represent another evolutionary
advantage that allows for regulation of Golgi functions by
external environmental cues.
In conclusion, we have defined GIV as a bona fide activator
of the trimeric G protein Gai at the Golgi and an effector
of active Arf1, and we have demonstrated that activation of
Gi by GIV serves the fundamental role of ensuring finiteness
of Arf1 signaling at the Golgi. Consequently, GIV regulates
both structure and function of the Golgi, two closely
intertwined processes regulated by Arf1. Thus, this work eluci-
dates some of the well-known, but poorly understood functions
of G proteins on intracellular membranes and impacts our un-
derstanding of trimeric G protein signaling in the secretory
pathway.
EXPERIMENTAL PROCEDURES
Detailed methods are stated in Supplemental Information.
Purification of GST-GAT protein and assessment of Arf1 activation were
described previously (Cohen and Donaldson, 2010). Immunofluorescence
and confocal microscopy was performed as described previously (Ghosh
et al., 2010).
PLA
These were done using a Duolink Kit (Sigma) according to the manufacturer’s
instructions.
FRET Studies
Previously validated internally tagged Gai1-YFP and CFP-Gb1g2 FRET probe
pairs were used (Bu¨nemann et al., 2003; Gibson and Gilman, 2006). FRET
efficiency was calculated on a pixel by pixel basis from the normalized ratio-
metric images obtained individually in donor, FRET, and acceptor channels.
For FRET quantification, regions of interest (ROI) were drawn in the juxtanu-
clear area presumably in the Golgi region to compute energy transfer. Individ-
ual cells with fluorescence intensity in the mesoscopic regime detected in the
donor and acceptor channels were selected for FRET analysis to avoid inho-
mogeneities between samples.
GFP-tsO45-VSVG Transport Assays
Tomonitor anterograde (ER toGolgi) trafficking, COS7 cells were treated over-
night with control or GIV siRNA and transiently transfected with GFP-tsO45-
VSVG plasmid (Presley et al., 1997). Transfected cells were incubated for
14–16 hr at the restrictive temperature (40C) to accumulate VSVG protein inDevethe ER, shifted to 32C for 0–60 min to release VSVG protein and then fixed
and processed for immunofluorescence. The rate of VSVG trafficking from
the ER to the Golgi was determined by calculating the ratio of Golgi-associated
VSVG, determined by colocalization with Man II, and total VSVG fluorescence,
using Image J (NIH) software.
Construction of a 3D Model of Arf1 Interaction with the N-Terminal
Helix-Loop-Helix Motif of GIV
The homology model of the Arf1:GIV complex was constructed using the
ICM comparative (homology) modeling procedure using the structure of
constitutively active Arf1 in complex with the N-terminal GAT domain of hu-
man GGA1 (PDB 1J2J) as a template and guided by the GIV/GGA1 sequence
alignment in Figure 6G. The initial model was generated by assigning the
backbone coordinates of both target molecules (Arf1 and GIV) to their coun-
terparts in the template. This model was further refined using extensive sam-
pling of residue side chains in internal coordinates and then additionally
relaxed by full-atom local minimization in the presence of distance restraints,
while maintaining the conserved hydrogen bonds, protein secondary struc-
ture, and topology.
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